Table S3.2 (in Table S3) shows that none of the four data sets is by itself sufficient to identify AMPK, and instead the use of all three supporting sets (transcriptional, SNP, drug targets) is necessary for its identification. The addition of OMIM, which represents the consolidated knowledge on AD and does not include AMPK (Table S3.1, in Table S3), has the effect of diluting the supporting evidence for new genes in favor of established ones, and brings the significance of AMPK below threshold. The gene discussed is PRKAA1; the disease is Alzheimer disease.